Take the challenge. C—This claim cannot be coded without querying the infusion nurse and physician. There must be documentation of the patient’s weight to document the correct dosage of the medication to be given to the patient. Also the start time and the completion time of the infusion must be documented to know which drug…
A 70–year-old female patient with rheumatoid arthritis affecting multiple joints who is rheumatoid-factor positive but without organ or system failure returns for her third infliximab infusion. She is scheduled to receive 500 mg of the drug. How should this encounter be coded? 96413, 96415, J1745 x 50; ICD 10: M05.79 96413, 96415, J1745 x 50;…
Improving access to rheumatology care for underserved patient populations is a priority for the ACR, and the subject of a major position statement by the Committee on Rheumatologic Care (CORC) in 2017. According to the ACR’s 2015 Workforce Study, the existing shortage of rheumatologists and rheumatology health professionals is expected to worsen in the next…
All 2018 ACR/ARHP Annual Meeting attendees received a complimentary, one-year ACR Beyond Streaming subscription. Recipients have access to all of the recorded sessions from the Annual Meeting, as well as more than 500 sessions from past meetings. In addition, they have the opportunity to view recorded sessions from upcoming 2019 educational meetings, including the Winter…
The Rheumatology Research Foundation has embarked on its third and most ambitious fundraising campaign, with a goal of raising $75 million. The Leading Boldly: Transforming Rheumatology campaign will support Foundation programs to recruit the best and brightest into the field, train rheumatology health professionals at all career stages and support investigators conducting research that will…
Researchers say a study of individual antibody response to citrullinated and non-citrullinated proteins in sputum samples further supports the importance of the lung in early development of rheumatoid arthritis-related autoimmunity. Investigation of the fundamental mechanism that leads to antibody responses in rheumatoid arthritis is key to uncovering ways to predict and prevent the development of…
A study published in the May issue of Arthritis Care & Research may be the first to examine the long-term outcomes of childhood-onset lupus, otherwise known as pediatric systemic lupus erythematosus (SLE), a chronic, multisystem autoimmune disease with a highly variable clinical course. Previous studies examined cross-sectional views of damage accrued. According to the Childhood…
Indigenous communities in Latin America lack good healthcare—and often lack any healthcare—for musculoskeletal and rheumatic diseases.1 Global health initiatives tend to focus on infectious disease, despite the increasing rate of chronic diseases. In a survey of 6,155 individuals from eight indigenous communities, conducted by a team of Latin American investigators, the prevalence of these conditions…
Recent data showing sustained, long-term safety and efficacy of mavrilimumab for the treatment of rheumatoid arthritis (RA) confirm and build on prior evidence from phase 2 studies of the potential for this new agent for the treatment of RA. Mavrilimumab is a human monoclonal antibody that blocks a proinflammatory cytokine involved in RA pathogenesis—granulocyte-macrophage colony-stimulating…
Psoriatic arthritis (PsA), like other inflammatory diseases, has been associated with increased incidence for and mortality from cardiovascular disease (CVD), the most common comorbidity leading to death in many conditions treated by rheumatologists. But beyond recognizing the burden of increased inflammation, the mechanisms behind this association are not well understood, says M. Elaine Husni, MD,…